Precision Medicine in Oncology® | Specialty

Sequencing in Hormone-Driven Metastatic Breast Cancer

June 16th 2017

Endocrine Resistance in HR+ Metastatic Breast Cancer

June 16th 2017

Emerging CDK4/6-Targeted Therapy for Breast Cancer

June 16th 2017

Choosing Therapy for HR+ Metastatic Breast Cancer

June 16th 2017

CDK4/6 Inhibitors for HR+ Metastatic Breast Cancer

June 16th 2017

FDA Approval of Ribociclib for Metastatic Breast Cancer

June 16th 2017

Keeping the Pathway Focus on Treatment Instead of Cost Will Ensure the Best Care

June 11th 2017

A divide has developed between pathways that primarily serve physicians and those that cater to payers that are trying to rein in costs.

Dr. Papadimitrakopoulou on Treatment Options for EGFR-Mutant NSCLC

June 2nd 2017

Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses treatment options for patients with EGFR-mutant non-small cell lung cancer (NSCLC).

Streamlining the Precision Medicine Process: It's Possible, Necessary, and Improves Care

May 28th 2017

Jonathan C. Trent, MD, PhD, discusses Sylvester Comprehensive Cancer Center’s ongoing efforts to advance the precision medicine process to improve patient care.

Biotech Executive Offers Glimpse of Testing Future

May 27th 2017

Foundation Focus CDx BRCA, can detect both germline and somatic BRCA1/2 mutations in women with ovarian cancer who are candidates for the PARP inhibitor rucaparib (Rubraca).

The Hunt for Biomarkers and Better Treatments in Advanced TNBC

May 21st 2017

In an OncLive Peer Exchange® discussion, experts in breast malignancies reviewed some exciting new developments in TNBC.

Optimal Sequencing in EGFR-Mutant NSCLC Remains a Work in Progress

May 15th 2017

Ramaswamy Govindan, MD, discusses the rapid therapeutic changes in NSCLC and the sequencing questions physicians are currently asking.

Expert Discusses Unleashing Promise of Genetic Testing in Prostate Cancer

May 8th 2017

Christopher J. Kane, MD, discusses the challenges and impact of genetic testing on patients with prostate cancer.

Expert Stresses Significance of Genetic Differences in Kidney Cancer

May 4th 2017

W. Marston Linehan, MD, discusses the landscape of kidney cancer, current clinical trials, and hope for the future of immunotherapy in this disease.

Gene Fusions Yield Increasingly Broad Spectrum of Targeted Therapies

May 3rd 2017

Thus far, only a small portion of known gene fusions have been tested with functional assays in an effort to understand if, and how, they drive cancer. Newly identified and well-established gene fusions alike continue to provide promising therapeutic targets and broaden our understanding of cancer development.

HER2+ Breast Cancer Heterogeneity Calls for Combos

May 2nd 2017

Targeted therapies have improved outcomes for HER2-positive breast cancer, which is characterized by an aggressive tumor phenotype and lower overall survival. However, questions remain on how to predict which patients will benefit from neoadjuvant or extended HER2-targeted therapies and how to treat patients with triple-positive breast cancer.

Dr. Gubens on Prevalence of EGFR/ALK/ROS1 and PD-L1 Expression in NSCLC

May 1st 2017

Matthew Gubens, MD, an assistant professor of thoracic oncology at the University of California San Francisco, discusses the prevalence of patients with non–small cell lung cancer (NSCLC) who harbor mutations in EGFR/ALK/ROS1 as well as PD-L1 expression.

Dr. Osborne Discusses Targeting the HER2 Pathway in Breast Cancer

April 18th 2017

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses targeting the HER2 pathway in breast cancer.

Expert Emphasizes Significance of Genetic Testing in Ovarian Cancer

April 14th 2017

Mike Janicek, MD sheds light on why physicians are slow to educate patients on testing, the detection of genes aside from BRCA1/2, and the lesser-known benefits of getting genetic testing early on in a diagnosis.

Dr. Quinn on Combinations of Targeted Therapy in RCC

April 11th 2017

David I. Quinn, MD, MBBS, associate professor of Medicine, medical director of USC Norris Cancer Hospital, on combinations of targeted therapies for patients with renal cell carcinoma (RCC).